Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Trial details
- Registry ID
- NCT05571059
- Drugs studied
- Ifetroban Sodium
TrialRedline tracks 4 clinical trials sponsored by Cumberland Pharmaceuticals: 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059 | Ifetroban Sodium | Recruiting | 2028-01Estimated |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511 | Oral Ifetroban | Active not recruiting | 2026-03Actual |
| Oral Ifetroban in Subjects With Duchenne Muscular DystrophyNCT03340675 | Ifetroban | Completed | 2024-03-06Actual |
| Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)NCT03028350 | Ifetroban Oral Capsule | Completed | 2023-04-25Actual |
Names as written in the registry records.
NCT02682511 · Cumberland Pharmaceuticals
Before: Estimated. After: Actual.
Before: Jun 2026. After: Mar 2026.
NCT05571059 · Cumberland Pharmaceuticals
Before: Jan 2027. After: Jan 2028.
NCT02682511 · Cumberland Pharmaceuticals
Before: Feb 2026. After: Jun 2026.
NCT03340675 · Cumberland Pharmaceuticals
Before: Active not recruiting. After: Completed.
NCT05571059 · Cumberland Pharmaceuticals
Before: Jan 2026. After: Jan 2027.
NCT03340675 · Cumberland Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events.
NCT03340675 · Cumberland Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-Emergent Adverse Events (safety & tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability).
Before: Estimated. After: Actual.
Before: 48 participants (planned). After: 46 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2025. After: 6 Mar 2024.